Role of Recombinant Alpha-Interferon in the Treatment of Advanced Cutaneous Malignant Melanoma
- 1 January 1991
- journal article
- clinical trial
- Published by S. Karger AG in Oncology
- Vol. 48 (5) , 365-368
- https://doi.org/10.1159/000226960
Abstract
A total of 65 patients with advanced cutaneous malignant melanoma (MM) have now been treated with interferon alpha-2b (Intron A) at a dose of 10 million IU/m2 administered subcutaneously thrice weekly. Fifty-one patients were evaluable for response, and 4 of these (7.8%) achieved complete remission; 2 of these 4 remain so at 37+ and 54+ months. Six additional patients achieved a partial remission. All responders had subcutaneous, lymph node and/or pulmonary metastases only. In all responders, therapy was continued for a total of 12 months. The vast majority of patients experienced side effects, largely flu-like symptoms, mild leukopenia and mild hepatocellular dysfunction. No evidence of cumulative toxicity was observed. Our experience indicates that interferon alpha-2b is active in patients with advanced cutaneous MM.Keywords
This publication has 0 references indexed in Scilit: